181 related articles for article (PubMed ID: 16132580)
1. Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest.
Bereczky B; Gilly R; Rásó E; Vágó A; Tímár J; Tóvári J
Clin Exp Metastasis; 2005; 22(1):69-76. PubMed ID: 16132580
[TBL] [Abstract][Full Text] [Related]
2. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival.
Sciumbata T; Caretto P; Pirovano P; Pozzi P; Cremonesi P; Galimberti G; Leoni F; Marcucci F
Invasion Metastasis; 1996; 16(3):132-43. PubMed ID: 9186548
[TBL] [Abstract][Full Text] [Related]
3. Antimetastatic activities of heparins and modified heparins. Experimental evidence.
Borsig L
Thromb Res; 2010 Apr; 125 Suppl 2():S66-71. PubMed ID: 20434009
[TBL] [Abstract][Full Text] [Related]
4. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.
Marchetti M; Vignoli A; Russo L; Balducci D; Pagnoncelli M; Barbui T; Falanga A
Thromb Res; 2008; 121(5):637-45. PubMed ID: 17692905
[TBL] [Abstract][Full Text] [Related]
5. Antimigratory and antimetastatic effect of heparin-derived 4-18 unit oligosaccharides in a preclinical human melanoma metastasis model.
Kenessey I; Simon E; Futosi K; Bereczky B; Kiss A; Erdödi F; Gallagher JT; Tímár J; Tóvári J
Thromb Haemost; 2009 Dec; 102(6):1265-73. PubMed ID: 19967160
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
7. The complex effects of heparins on cancer progression and metastasis in experimental studies.
Smorenburg SM; Van Noorden CJ
Pharmacol Rev; 2001 Mar; 53(1):93-105. PubMed ID: 11171940
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung.
Niers TM; Brüggemann LW; Klerk CP; Muller FJ; Buckle T; Reitsma PH; Richel DJ; Spek CA; Van Tellingen O; Van Noorden CJ
Clin Exp Metastasis; 2009; 26(3):171-8. PubMed ID: 19067186
[TBL] [Abstract][Full Text] [Related]
9. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo.
Ludwig RJ; Alban S; Bistrian R; Boehncke WH; Kaufmann R; Henschler R; Gille J
Thromb Haemost; 2006 Mar; 95(3):535-40. PubMed ID: 16525583
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of low-molecular-weight heparin and unfractionated heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers. An in vitro study and review of the literature.
Lersch C; Gericke D; Classen M
Urol Int; 1996; 56(4):230-3. PubMed ID: 8776820
[TBL] [Abstract][Full Text] [Related]
11. The heparins and cancer: review of clinical trials and biological properties.
Castelli R; Porro F; Tarsia P
Vasc Med; 2004 May; 9(3):205-13. PubMed ID: 15675186
[TBL] [Abstract][Full Text] [Related]
12. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis.
Sola F; Farao M; Ciomei M; Pastori A; Mongelli N; Grandi M
Invasion Metastasis; 1995; 15(5-6):222-31. PubMed ID: 8765197
[TBL] [Abstract][Full Text] [Related]
13. Antitumor and antimetastatic effect of warfarin and heparins.
Bobek V; Kovarík J
Biomed Pharmacother; 2004 May; 58(4):213-9. PubMed ID: 15183845
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
15. Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo.
Zhang C; Liu Y; Gao Y; Shen J; Zheng S; Wei M; Zeng X
Int J Cancer; 2009 Nov; 125(9):2058-65. PubMed ID: 19598263
[TBL] [Abstract][Full Text] [Related]
16. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models.
Alyahya R; Sudha T; Racz M; Stain SC; Mousa SA
Int J Oncol; 2015 Mar; 46(3):1225-31. PubMed ID: 25530018
[TBL] [Abstract][Full Text] [Related]
17. Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.
Lee DY; Park K; Kim SK; Park RW; Kwon IC; Kim SY; Byun Y
Clin Cancer Res; 2008 May; 14(9):2841-9. PubMed ID: 18451252
[TBL] [Abstract][Full Text] [Related]
18. A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis.
Chen Y; Peng J; Han M; Omar M; Hu D; Ke X; Lu N
J Drug Target; 2015 May; 23(4):335-46. PubMed ID: 25541466
[TBL] [Abstract][Full Text] [Related]
19. Antimetastatic effect of recombinant human macrophage-colony-stimulating factor against lung and liver metastatic B16 melanoma.
Sakurai T; Yamada M; Simamura S; Motoyoshi K
Cancer Immunol Immunother; 1997 Mar; 44(1):48-54. PubMed ID: 9111584
[TBL] [Abstract][Full Text] [Related]
20. Binding between heparin and the integrin VLA-4.
Schlesinger M; Simonis D; Schmitz P; Fritzsche J; Bendas G
Thromb Haemost; 2009 Nov; 102(5):816-22. PubMed ID: 19888514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
